Table 1.
Baseline Characteristics of Patients With Lung Cancer
| Receiving Targeted Therapy N = 35 | Without Targetable Mutations N= 119 | P | |
|---|---|---|---|
| Age in years, median (range) | 60.6 (31.4–83.6) | 65.5 (43.9–84.0) | 0.004 |
| Female gender, n (%) | 23 (65.7) | 58 (48.7) | 0.08 |
| Race/ethnicity, n (%) | |||
| White | 30 (85.7) | 107 (89.9) | 0.21 |
| American Indian/Alaskan Native | 0 | 2 (1.7) | |
| Asian | 3 (7.7) | 1 | |
| Black | 1 (2.9) | 4 (3.4) | |
| Hispanic | 0 | 1 (0.8) | |
| Other | 1 (2.9) | 4 (3.4) | |
| Smoking, n (%) | |||
| Never smoker/ <10 pack years | 27 (77.1) | 19 (16.0) | <0.001 |
| > 10 pack-years | 7 (20.0) | 98 (82.4) | |
| Comorbidity (CCI), mean (SD) | 6.6 (1.1) | 7.1 (1.2) | 0.05 |
| Performance status at enrollment, n (%) | |||
| 0 | 10 (28.6) | 25 (21.0) | 0.63 |
| 1 | 23 (65.7) | 85 (71.4) | |
| 2 | 2 (5.7) | 9 (7.6) | |
| Brain metastases at diagnosis, n (%) | 16 (45.7) | 35 (29.4) | 0.07 |
| Mutation, n (%) | |||
| EGFR | 26 (74.3) | - | |
| ALK | 7 (20.0) | - | |
| ROS1 | 2 (5.7) | ||
| Treatment regimen Chemotherapy | |||
| First line | 10 (28.6) | 111 (93.3) | |
| Second line | 11 (31.4) | 49 (41.2) | |
| Tyrosine kinase inhibitor (TKI) | |||
| First line | 24 (68.6) | 3 (2.5) | |
| Second line | 26 (74.3) | 2 (1.7) | |
| Lines of therapy, mean (SD) | 3.6 (2.1) | 2.2 (1.4) | 0.0001 |
| Randomized to receive palliative care | 23 (65.7) | 57 (47.9) | 0.06 |